InvestorsHub Logo
Followers 86
Posts 1770
Boards Moderated 0
Alias Born 09/03/2009

Re: None

Tuesday, 10/17/2017 2:34:58 PM

Tuesday, October 17, 2017 2:34:58 PM

Post# of 8449
Reminder of the tantalizing potential of TyrNovo's NT219:

""Based on the pre-clinical results generated to date, we are receiving solid preliminary interest from potential strategic partners for NT219, which presents a novel, first-in-class mechanism of action in the oncology field."

A quote in KTOV's press release of October 6, 2017.

Kitov now OWNS 97% of TyrNovo. NT219 is made for a BIG partner since it converts ineffective (patented) chemo drugs to effective in many types of cancer thus far in the lab.

Millstone